title: Oral chemotherapy food and drug interactions: a comprehensive review of the literature.
abstract: BACKGROUND
  Oral chemotherapy is rapidly becoming a popular dosage form for cancer treatment. These medications have a narrow therapeutic index, and their metabolism can be easily affected by food and/or drug interactions. These interactions can significantly reduce the effectiveness of oral chemotherapy, which could possibly result in harm to patients.
  
  
  METHODS
  A systematic evaluation of 58 oral chemotherapeutics was conducted. Drug and food interactions were analyzed using US Food and Drug Administration-approved product labeling, primary literature, and tertiary databases.
  
  
  RESULTS
  Our evaluation identified information about drug and food interactions. We present the recommended dose adjustments in our article.
  
  
  CONCLUSIONS
  Oral chemotherapy is associated with a significant number of medication and food interactions. It is essential that health care providers evaluate patients' diet and concurrent medications to provide accurate patient education, therapeutic monitoring, and, if necessary, alternative recommendations whenever oral chemotherapy is prescribed.
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI eve-michelle.segal@froedtert.com.
authors.forename: Eve M
authors.initials: EM
authors.lastname: Segal
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Megan R
authors.initials: MR
authors.lastname: Flood
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Mancini
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Whiteman
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Friedt
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Adam R
authors.initials: AR
authors.lastname: Kramer
authors.affiliation: Confluence Health Wenatchee Valley Medical Clinics, Wenatchee, WA; St Luke's Mountain States Tumor Institute; St Luke's Regional Medical Center, Boise, ID; and Froedtert and The Medical College of Wisconsin, Milwaukee, WI.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Hofstetter
mesh_terms: D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D004348:Drug Labeling; D004358:Drug Therapy; D018565:Food-Drug Interactions; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D003577:Cytochrome P-450 Enzyme System